Low-titer group O whole blood has spread through civilian trauma resuscitation, and in practice it is RhD-positive, because RhD-negative whole blood is scarce. When it goes into an RhD-negative patient — or one whose type is not yet known — who still has reproductive potential, it can cause anti-D alloimmunisation. The harm does not show up that night. It shows up in a pregnancy years later, as haemolytic disease of the fetus and newborn.
That risk was accepted on a specific premise: that whole blood bought a survival advantage large enough to be worth it. Two randomised trials of prehospital traumatic haemorrhage found no survival advantage for whole blood over component therapy. This commentary in Obstetrics and Gynecology argues that with the premise gone, the trade-off cannot be justified when compatible product is available.
What makes this different from other transfusion risks is that it is entirely preventable by product selection, and it falls on patients who cannot consent while they are being resuscitated. The authors ask institutions to default patients with reproductive potential to RhD-negative product until the type is confirmed, and to guarantee standardised, cost-free follow-up when an incompatible transfusion does happen.
- Ask your trauma service what their default product is for a young patient of unknown RhD type
- Anti-D prophylaxis after an RhD-incompatible transfusion needs dosing against the red cell volume given, not the obstetric standard dose
- Document the transfusion where an antenatal clinic will find it years later — this is the failure point
- Any patient with reproductive potential who received RhD-positive product needs an antibody screen at booking, not just at 28 weeks
- Raise it with blood bank before the next mass transfusion protocol review, not after the next case
Why it matters
A risk that only appears in a future pregnancy has been priced against a survival benefit that two trials could not find.
Don't overread it
This is an ethics and policy argument built on the trials, not a trial of transfusion strategy in this population.
The statistics, in plain English
The argument here turns on two null trials rather than a new finding. 'No survival advantage' means the trials did not detect one — it does not prove the two products are identical. But the burden of proof sat with whole blood, because accepting a preventable future harm needed a demonstrated benefit to offset it. Without that benefit, the default flips back.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free